Site icon America's Favorite Eye Doctor – Eye Diseases – Dr Kondrot – Healing the Eye

Treating the Eye with the Microcurrent Stimulation (MCS)

Microcurrent Stimulation (MCS) is a treatment process for an eye, which everyone is not well aware of, this article will help you understand the treatment and apprehend its working along with its benefits.

Microcurrent stimulation is a technique to apply electrical stimulation to nerve pathways utilizing cutaneous electrodes. However, in general terms, microcurrent stimulation can be understood as the treatment that helps in stimulating energy production (ATP) within the retina, reduce waste build-up and improves circulation.

Microcurrent stimulation for macular degeneration is also described as employing 200 microamperes of power in the nine-volt battery to eight points across the eye. This advanced technique utilizes lower currents, within the range of 50 to 500 microamperes. The device control renders the microcurrent with two different waveforms and four different frequencies.

How Does The Process Work?

The therapy of patients with Macular Degeneration and Retinitis Pigmentosa involves periodic management of extremely definite quantities of closely controlled electric current through electrodes, applied to the skin at specific areas around the eye. The electrical current is primarily practiced to stimulate the retina as well as the diseased macula to improve and protect eyesight. The procedure is safe, noninvasive and painless without any side effects or adverse reactions.

The higher frequencies of the microcurrent, in the beginning, are of the 5-minute session each, which helps in relaxing the retinal tissues. Further, the lower frequencies stimulate the retina and ATP production in the cells of the retina. The treatment is also efficient in attracting adult stem cells and making them functional to help stimulate any possible cell regeneration.

Here are some major benefits of MCS as a treatment:

Microcurrent stimulation of the macula was introduced as a treatment for patients with AMD (Age-related macular degeneration), as it’s the principal cause of the irreversible and severe central visual reduction in Americans 50 decades and older. Usually, patients who advance to the neovascular form of the illness or have geographical atrophy between the foveal center are more prone to develop the condition of severe vision loss. Laser photocoagulation, photodynamic therapy with verteporfin, and particular nutritional supplements are treatments that have demonstrated efficacy in randomized controlled trials for certain stages of AMD.

Rate this post
Exit mobile version